Journal article
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
Abstract
PURPOSE: SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid 18F-rhPSMA-7.3, a novel high-affinity positron emission tomography radiopharmaceutical.
MATERIALS AND METHODS: Men with prostate cancer recurrence underwent positron emission tomography/CT 50-70 minutes after intravenous administration of 296±20% MBq 18F-rhPSMA-7.3. To assess the coprimary end points (verified detection rate and combined region-level …
Authors
Jani AB; Ravizzini GC; Gartrell BA; Siegel BA; Twardowski P; Saltzstein D; Fleming MT; Chau A; Davis P; Chapin BF
Journal
Journal of Urology, Vol. 210, No. 2, pp. 299–311
Publisher
Wolters Kluwer
Publication Date
August 2023
DOI
10.1097/ju.0000000000003493
ISSN
0021-0005